Coronavirus Update: Praised By Trump, Regeneron Files Antibody Cocktail For Emergency Use Authorization

Plus: India Blocks Russian Vaccine Trials

Trump's praise of the therapy and talk of a 'cure' for COVID-19 has raised concerns about misinformation and pressure on the US FDA once again.  

Regeneron
Regeneron believes it has enough data to support an EUA - but Trump's unfounded claims of a 'cure' muddy the water.

Regeneron Pharmaceuticals, Inc. has filed its monoclonal antibody therapy REGN-COV2 with the US Food and Drug Administration for emergency use authorization, announcing the submission just hours after President Trump praised it as a "cure" for COVID-19.

Discussions with the US regulator about a potential EUA had already begun after the company announced promising results two weeks...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from COVID-19

More from Scrip